Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
The US Justice Department charged Israeli generic drug firm Teva for conspiring to price-fixing, rigging bids, and allocating customers for generic drugs between 2013 and 2015.
The alleged transgressions caused patients to overpay by over $350 million.
Among the generic drugs was the cholesterol-regulating Pravastatin.
Teva, which sold $17 billion worth of drugs last year, rejected the charges saying it was “deeply disappointed" that the government proceeded with the prosecution.
It added that the US was unwilling to consider alternatives that would not be as impactful.
Five companies investigated in the case, including Sandoz, Taro, and Apotex have already paid fines to avoid prosecution.
Sandoz paid $195 million in March, while Apotex agreed to a $24.1 million fine in May.
In July, the American subsidiary of Israel's Taro Pharmaceuticals paid $205.7 million.
Earlier this month, Teva was also accused of inflating the reimbursement price for its multiple sclerosis drug, Copaxone, for patients in the Medicare program.
